- Molecular NameRasagiline
- SynonymRAS
- Weight171.243
- Drugbank_IDDB01367
- ACS_NO1875-50-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.92
- pkaN/A
- LogD (pH=7, predicted)1.22
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.88
- LogSw (predicted, AB/LogsW2.0)1.0
- Sw (mg/ml) (predicted, ACD/Labs)1.2
- No.of HBond Donors1
- No.of HBond Acceptors1
- No.of Rotatable Bonds3
- TPSA12.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Absorption_valueN/A
- Absorption (description)Rasagiline is rapidly absorbed following oral administration.
- Caco_2N/A
- Bioavailability36.0
- Protein binding91.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.
- Half life3 h
- ExcretionRenal and fecal; 62% of total dose in urine and 7% of total dose in feces over 7 days
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
- LD50 (rat)N/A
- LD50 (mouse)N/A